<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02633046</url>
  </required_header>
  <id_info>
    <org_study_id>MNK14224049</org_study_id>
    <nct_id>NCT02633046</nct_id>
  </id_info>
  <brief_title>Acthar for Treatment-Resistant or Treatment-Intolerant Proteinuria</brief_title>
  <acronym>PODOCYTE</acronym>
  <official_title>Treatment of Proteinuria Due to Treatment Resistant or Treatment Intolerant Idiopathic Focal Segmental Glomerulosclerosis: A Prospective Study of Acthar (PODOCYTE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Focal segmental glomerulosclerosis (FSGS) is a condition that harms the kidney &quot;filters&quot; that
      remove waste from the blood. Proteins are supposed to stay in the blood. Damaged &quot;filters&quot;
      let protein get into the kidney.

      FSGS is a serious condition that can lead to kidney failure. The only treatment for kidney
      failure is dialysis or kidney transplant.

      Proteinuria means too much protein came through the kidneys into the urine.

      If the doctor cannot figure out what is causing the problem, it is primary (idiopathic) FSGS.
      This kind of FSGS is very hard to treat.

      This study will test Acthar in patients with this condition who have not responded to other
      treatments. It will measure how much the protein level went down in their urine by using
      Acthar.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Anticipated">August 28, 2020</completion_date>
  <primary_completion_date type="Anticipated">August 28, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The trial has three periods with potentially different trial designs (based on remission status):
Period 1: (Baseline to Week 23) All participants, open-label Acthar
Period 2: (Starting Week 26)
Participants who did not achieve remission in Period 1 continue on open-label Acthar to Week 50 (followed by 2 weeks of tapering); they enter Period 3 at Week 52.
Participants who did achieve remission are randomized to take either Acthar or Placebo to Week 50. They enter Period 3 at Week 50.
Period 3: All participants have a 4-week safety follow-up (within 56 weeks)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>Participants and investigator were blinded only to randomized treatment during Period 2</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Total protein in a 24-hour urine sample</measure>
    <time_frame>within 56 weeks</time_frame>
    <description>Total protein is measured in 24-hour urine samples</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Idiopathic Focal Segmental Glomerulosclerosis</condition>
  <arm_group>
    <arm_group_label>Period 1: Acthar Open-Label</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants receive open-label treatment with Acthar 80 U 3x/week, tapering to 2x per week if needed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: Randomized to Acthar</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive Acthar 80 U 2x/week through Week 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: Randomized to Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive Placebo 2x/week through Week 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 2: Open-label Acthar</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Participants continue open-label treatment with Acthar 80 U 3x/week through Week 50, followed by a 2-week tapering period (within 52 weeks)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Period 3: Safety Follow-up</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>All participants receive no intervention during a 4-week safety follow-up period, so the study completion date for each participant is within 56 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 3x/week</intervention_name>
    <description>Acthar 80 U 3x/week</description>
    <arm_group_label>Period 1: Acthar Open-Label</arm_group_label>
    <arm_group_label>Period 2: Open-label Acthar</arm_group_label>
    <other_name>Acthar Gel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo 2x/week</description>
    <arm_group_label>Period 2: Randomized to Placebo</arm_group_label>
    <other_name>Matching Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acthar 80 U 2x/week</intervention_name>
    <description>Acthar 80 U 2x/week</description>
    <arm_group_label>Period 1: Acthar Open-Label</arm_group_label>
    <arm_group_label>Period 2: Randomized to Acthar</arm_group_label>
    <other_name>Acthar Gel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Potential participants must meet the following summary criteria for inclusion in the study:

          -  Is male or non-pregnant, non-lactating female

          -  Has primary FSGS, is nephrotic and did not achieve at least partial proteinuria
             response with prior therapy

          -  Has been treated with an angiotensin converting enzyme inhibitor or receptor blocker
             (or have documented intolerance), for at least 4 weeks before screening

          -  Has blood pressure no higher than 150/90 mmHg

          -  Meets all other inclusion criteria detailed in the protocol

        Exclusion Criteria

        Potential participants will not be eligible for the the study if they meet the following
        summary criteria:

          -  Has hepatitis B or C, tuberculosis, or other contraindication listed on the United
             States (US) Prescribing Information for Acthar

          -  Has Type 1 or Type 2 diabetes mellitus or any clinically significant infection

          -  Has received specific treatments at exclusionary time points per protocol

          -  Has been involved in a therapeutic drug/device trial (other than for FSGS) within 4
             weeks before screening

          -  Meets any other exclusion criteria detailed in the protocol

          -  Has any other condition that might, per protocol or in the opinion of the
             investigator, compromise:

               1. the safety and well-being of the participant or their offspring

               2. the safety of study staff

               3. analysis of results
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Team Leader</last_name>
    <role>Study Director</role>
    <affiliation>Mallinckrodt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AKDHC Medical Research Services, LLC</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Institute of Renal Research</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VERITAS Research Corp</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Clinical Research Corp</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GA Nephrology</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NANI Research</name>
      <address>
        <city>Hinsdale</city>
        <state>Illinois</state>
        <zip>60521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Louisville Research Foundation, Inc.</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation, Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NKDHC Medical Research Services, LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine-Mt. Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metrolina Nephrology Associates</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates, LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati Physicians Company, LLC</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati VA Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Tech University Health Science Center</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Kidney Institute (Neprhotex Research Group)</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Wisconsin Dialysis Institute</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Salud Renal Junín SRL</name>
      <address>
        <city>Junín</city>
        <state>BA</state>
        <zip>B6000GPB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas</name>
      <address>
        <city>Mar del Plata</city>
        <state>BA</state>
        <zip>B7600FYK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Allende</name>
      <address>
        <city>Córdoba</city>
        <zip>X5000JHQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Renal Research Group</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool Hospital</name>
      <address>
        <city>Liverpool</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Westmead Hospita</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Launceston Hospital</name>
      <address>
        <city>Launceston</city>
        <state>Tasmania</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sunshine Hopital - Western Health</name>
      <address>
        <city>St Albans</city>
        <state>Victoria</state>
        <zip>3021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Hernán Henríquez Aravena</name>
      <address>
        <city>Temuco</city>
        <state>IX Region</state>
        <zip>4781151</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Davila</name>
      <address>
        <city>Santiago</city>
        <state>RM</state>
        <zip>8340518</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigación Nefrológica SC</name>
      <address>
        <city>Cuernavaca</city>
        <state>Morelos</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital y Clínica OCA S.A de C.V</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo Leon</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Cayetano Heredia</name>
      <address>
        <city>San Martin de Porres</city>
        <state>Lima</state>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Hospital Maria Auxiliadora</name>
      <address>
        <city>Lima Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Alberto Sabogal</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Nacional Arzobispo Loayza</name>
      <address>
        <city>Lima</city>
        <country>Peru</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Şişli Etfal Hamidiye Training and Research Hospital</name>
      <address>
        <city>İstanbul</city>
        <state>Sisli</state>
        <zip>034360</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>İstanbul University Faculty of Medicine</name>
      <address>
        <city>İstanbul</city>
        <state>Topkapi</state>
        <zip>34093</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara NumuneTraining and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara Training and Research Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>İstanbul University Faculty of Medicine</name>
      <address>
        <city>İstanbul</city>
        <zip>34098</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kocaeli University Faculty of Medicine</name>
      <address>
        <city>Kocaeli</city>
        <zip>41380</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marmara University Faculty of Medicine</name>
      <address>
        <city>Maltepe</city>
        <zip>34840</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mersin University Faculty of Medicine</name>
      <address>
        <city>Mersin</city>
        <zip>33000</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Peru</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>Hong Kong</country>
    <country>New Zealand</country>
    <country>Puerto Rico</country>
  </removed_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>December 15, 2015</study_first_submitted>
  <study_first_submitted_qc>December 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2015</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FSGS</keyword>
  <keyword>primary FSGS</keyword>
  <keyword>idiopathic FSGS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Proteinuria</mesh_term>
    <mesh_term>Glomerulosclerosis, Focal Segmental</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adrenocorticotropic Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

